Creon Market Report 2026

Creon Market Overview

• The Creon market growth in the historic period has been driven by established efficacy of pancrelipase, rising cystic fibrosis population • Market expansion is supported by growth in chronic digestive disorders, rising aging population • Growth Driver: Rising Prevalence Of Pancreatic Disorders Drives Growth In The Creon Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Creon Market?

Creon is a prescription medication that contains pancrelipase, a combination of digestive enzymes including lipase, protease, and amylase. These enzymes are normally produced by the pancreas to help digest food. Creon is used to treat conditions where the pancreas does not produce enough of these enzymes, such as in cystic fibrosis, chronic pancreatitis, or after pancreatic surgery. By supplementing the body's enzyme supply, Creon helps improve the digestion and absorption of fats, proteins, and carbohydrates, which are essential nutrients. It is taken orally with meals and snacks to aid digestion. The main types of creon treatment include nutritional management and pancreatic enzyme replacement therapy (pert). Nutritional management refers to the process of planning and controlling a person's diet to support health, recovery, and optimal well-being. It is used for abdominal pain, constipation, diarrhea, fatty stools, and weight loss and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Creon Market Growth Forecast?

The growth in the forecast period can be attributed to growth in chronic digestive disorders, rising aging population, improved nutritional management focus, expansion of outpatient digestive care, increased awareness of enzyme deficiencies. Major trends in the forecast period include strong adoption of pancrelipase based therapies, growing focus on pancreatic enzyme replacement therapy, expansion of long term digestive disorder management, improved patient compliance through optimized dosing, rising use in post pancreatic surgery care.

Global Creon Market Segmentation

1) By Treatment: Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT) 2) By Symptom: Abdominal Pain, Constipation, Diarrhea, Fatty Stools, Weight Loss 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

What Are The Drivers Of The Creon Market?

The rising prevalence of pancreatic disorders is expected to fuel the growth of the creon market going forward. Pancreatic disorders are a group of conditions that affect the pancreas, impairing its ability to produce digestive enzymes and/or insulin, leading to problems with digestion, blood sugar regulation, and overall health. Pancreatic disorders are rising due to factors such as increased rates of chronic alcohol consumption, smoking, obesity, diabetes, and genetic predispositions, along with improved diagnostic techniques leading to greater detection. Creon is used to manage pancreatic disorders by supplementing digestive enzymes to aid in the digestion and absorption of nutrients. For instance, in February 2023, according to a report published by Cancer Research UK, a UK-based cancer research organization, the number of new pancreatic cancer cases in the UK is projected to increase from approximately 12,500 cases annually between 2023 and 2025 to around 16,000 cases by 2038-2040. It is anticipated that the incidence of pancreatic cancer will increase by 5% between 2023–2025 and 2038–2040, averaging 19 cases per 100,000 years by that time. Therefore, the rising prevalence of pancreatic disorders is driving the growth of the creon industry. The growing focus on personalized medicine is expected to fuel the growth of the creon market going forward. Personalized medicine is a medical approach that customizes treatment based on an individual patient's genetic makeup, environment, and lifestyle to optimize effectiveness and minimize adverse effects. The growing focus on personalized medicine is driven by advances in genetics, better disease understanding, the demand for more effective treatments, and the use of technology such as AI to create tailored therapies. Personalized medicine positively impacts creon by enabling more precise enzyme replacement therapy tailored to individual patients' specific pancreatic conditions, improving treatment efficacy and patient outcomes. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. Therefore, the increasing demand for personalized medicine is driving the growth of the creon industry. The rising healthcare expenditure is expected to boost the growth of the creon market going forward. Healthcare expenditure refers to the total spending on medical services, treatments, pharmaceuticals, and healthcare infrastructure. The rising healthcare expenditure is attributed to factors such as aging populations, increased demand for medical services, higher costs of treatments, and advancements in healthcare technology. Healthcare expenditure plays a crucial role in the accessibility and affordability of Creon for patients with pancreatic disorders, impacting its widespread use and availability. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, between 2022 and 2023, healthcare spending in the UK increased by 5.6% compared with growth of 0.9% in 2022. Therefore, the increasing demand for healthcare expenditure is driving the growth of the creon industry.

Key Players In The Global Creon Market

Major companies operating in the creon market are AbbVie Inc.

Regional Insights

North America was the largest region in the creon market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Creon Market?

The creon market consists of sales of pancreatic enzyme supplements, digestive health supplements, pancreatic enzyme replacement therapy (PERT) devices, and nutritional supplements for digestive health. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Creon Market Report 2026?

The creon market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the creon industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.